Basilea News http://www.basilea.com/ Basilea News en Thu, 02 Jul 2015 14:29:01 +0200 Thu, 02 Jul 2015 14:29:01 +0200 Chameleon CMS webmaster@basila.com (Webmaster Webmaster) webmaster@basila.com (Webmaster Webmaster) <![CDATA[Basilea initiates phase 1/2a oncology study with oral formulation of tumor checkpoint controller BAL101553]]> http://www.basilea.com/News-and-Media/Basilea-initiates-phase-1-2a-oncology-study-with-oral-formulation-of-tumor-checkpoint-controller-BAL101553/e8b0d2b5-df5a-5eaf-ed49-a24b1e981d6a Thu, 25 Jun 2015 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-initiates-phase-1-2a-oncology-study-with-oral-formulation-of-tumor-checkpoint-controller-BAL101553/e8b0d2b5-df5a-5eaf-ed49-a24b1e981d6a <![CDATA[Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor]]> http://www.basilea.com/News-and-Media/Basilea-reports-start-of-first-in-human-phase-1-oncology-study-with-oral-panRAF-kinase-inhibitor/407433b0-37e7-b20b-53c1-c405cce13192 Mon, 04 May 2015 19:38:45 +0200 http://www.basilea.com/News-and-Media/Basilea-reports-start-of-first-in-human-phase-1-oncology-study-with-oral-panRAF-kinase-inhibitor/407433b0-37e7-b20b-53c1-c405cce13192 <![CDATA[Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders]]> http://www.basilea.com/News-and-Media/Basilea-shareholders-approve-all-resolutions-proposed-by-the-Board-of-Directors-at-the-Ordinary-General-Meeting-of-Shareholders/7fe480dc-bd41-b275-5dea-141918a121b9 Wed, 29 Apr 2015 17:57:42 +0200 http://www.basilea.com/News-and-Media/Basilea-shareholders-approve-all-resolutions-proposed-by-the-Board-of-Directors-at-the-Ordinary-General-Meeting-of-Shareholders/7fe480dc-bd41-b275-5dea-141918a121b9 <![CDATA[Basilea reports isavuconazole and ceftobiprole data to be presented at ECCMID]]> http://www.basilea.com/News-and-Media/Basilea-reports-isavuconazole-and-ceftobiprole-data-to-be-presented-at-ECCMID/4e2c5bf7-ad8b-7c66-c933-cc88ab9436b0 Fri, 24 Apr 2015 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-reports-isavuconazole-and-ceftobiprole-data-to-be-presented-at-ECCMID/4e2c5bf7-ad8b-7c66-c933-cc88ab9436b0 <![CDATA[Basilea in-licenses targeted cancer therapy]]> http://www.basilea.com/News-and-Media/Basilea-in-licenses-targeted-cancer-therapy/7593c3a4-0959-18e7-2e1d-2df5872064a1 Wed, 01 Apr 2015 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-in-licenses-targeted-cancer-therapy/7593c3a4-0959-18e7-2e1d-2df5872064a1 <![CDATA[Basilea reports U.S. FDA approval of isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis]]> http://www.basilea.com/News-and-Media/Basilea-reports-U-S-FDA-approval-of-isavuconazole-for-the-treatment-of-invasive-aspergillosis-and-invasive-mucormycosis/b5a4bddf-f2f4-0e01-34d0-94ae3bef0367 Fri, 06 Mar 2015 23:02:16 +0100 http://www.basilea.com/News-and-Media/Basilea-reports-U-S-FDA-approval-of-isavuconazole-for-the-treatment-of-invasive-aspergillosis-and-invasive-mucormycosis/b5a4bddf-f2f4-0e01-34d0-94ae3bef0367 <![CDATA[Basilea reports solid 2014 full-year results, preparing the ground for commercialization of Zevtera® in Europe]]> http://www.basilea.com/News-and-Media/Basilea-reports-solid-2014-full-year-results-preparing-the-ground-for-commercialization-of-Zevtera-in-Europe/76ba029f-5dba-e614-d283-9cc048a66e5a
  • Antifungal isavuconazole U.S. NDA and European MAA submissions under regulatory review - decisions expected in Q1 2015 in the U.S. and Q4 2015 in the EU
  • First commercial launch of antibiotic Zevtera® (ceftobiprole medocaril)
  • Cash and short-term investments of CHF 226 million
  • ]]>
    Tue, 17 Feb 2015 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basilea-reports-solid-2014-full-year-results-preparing-the-ground-for-commercialization-of-Zevtera-in-Europe/76ba029f-5dba-e614-d283-9cc048a66e5a
    <![CDATA[Basilea announces that FDA's Anti-Infective Drugs Advisory Committee recommends approval of isavuconazole for the treatment of invasive aspergillosis and mucormycosis]]> http://www.basilea.com/News-and-Media/Basilea-announces-that-FDAs-Anti-Infective-Drugs-Advisory-Committee-recommends-approval-of-isavuconazole-for-the-treatment-of-invasive-aspergillosis-and-mucormycosis/98020376-b768-57bf-9bf0-8e0d76ba00b3 Thu, 22 Jan 2015 21:07:41 +0100 http://www.basilea.com/News-and-Media/Basilea-announces-that-FDAs-Anti-Infective-Drugs-Advisory-Committee-recommends-approval-of-isavuconazole-for-the-treatment-of-invasive-aspergillosis-and-mucormycosis/98020376-b768-57bf-9bf0-8e0d76ba00b3 <![CDATA[Swissmedic approves Basilea's antibiotic Zevtera® (ceftobiprole medocaril) for the treatment of pneumonia]]> http://www.basilea.com/News-and-Media/Swissmedic-approves-Basileas-antibiotic-Zevtera-ceftobiprole-medocaril-for-the-treatment-of-pneumonia/e9e4a43a-48a9-da83-7434-95a81b9c6eb0 Mon, 22 Dec 2014 07:15:00 +0100 http://www.basilea.com/News-and-Media/Swissmedic-approves-Basileas-antibiotic-Zevtera-ceftobiprole-medocaril-for-the-treatment-of-pneumonia/e9e4a43a-48a9-da83-7434-95a81b9c6eb0 <![CDATA[Basilea announces launch of antibiotic Zevtera® (ceftobiprole medocaril) in Germany]]> http://www.basilea.com/News-and-Media/Basilea-announces-launch-of-antibiotic-Zevtera-ceftobiprole-medocaril-in-Germany/59334b49-49f7-9596-c42f-93124a0d5979
  • First commercial launch
  • ]]>
    Fri, 05 Dec 2014 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basilea-announces-launch-of-antibiotic-Zevtera-ceftobiprole-medocaril-in-Germany/59334b49-49f7-9596-c42f-93124a0d5979